Please select the option that best describes you:
Will you offer adjuvant T-DM1 for patients with HER2+ breast cancer who have residual invasive disease following neoadjuvant therapy?
Will you incorporate the results from KATHERINE into clinical practice now?
Answer from: Medical Oncologist at Academic Institution
The KATHERINE trial was presented at this years San Antonio Breast Cancer Symposium and published on line in the NEJM Dec 5. The trial was a phase III randomized trial for women who residual disease post-neoadjuvant HER2-targeted chemotherapy regimens. The randomization was to 1:1 with either trastu...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Yes, I would argue that the KATHERINE trial data results in a treatment paradigm shift and that T-DM1 is the standard of care in patients with residual disease after neoadjuvant chemotherapy plus HER2-directed therapy. The results were reported at the 2018 San Antonio Breast Cancer Symposium and pub...
Answer from: Medical Oncologist at Community Practice
Yes, I will. The Katherine trial showed an 11.3% improvement in invasive disease free survival at 3 years for patients rdceiving T-DM1 instead of trastuzumab after neoadjuvant therapy with chemo + anti-HER-2 agents.